Prevention and management of drug resistance for antihepatitis B treatment (Q37424372)

20 August 2017

1 reference

title

Prevention and management of drug resistance for antihepatitis B treatment (English)

1 reference

20 August 2017

James Fung

2

0 references

Ching-Lung Lai

object named as

Ching-Lung Lai

series ordinal

4

0 references

author name string

Man-Fung Yuen

series ordinal

1

1 reference

PubMed ID

19324298

20 August 2017

Danny Ka-Ho Wong

series ordinal

3

1 reference

20 August 2017

1 April 2009

1 reference

Lancet Infectious Diseases

20 August 2017

1 reference

20 August 2017

9

1 reference

20 August 2017

4

1 reference

20 August 2017

256-264

1 reference

Mutation rate of the hepadnavirus genome

20 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Viral dynamics in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: theoretical considerations.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Inhibition of hepatitis B virus polymerase by entecavir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Antiviral therapy of chronic hepatitis B: prevention of drug resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Antiviral-resistant hepatitis B virus: can we prevent this monster from growing?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Variant of hepatitis B virus with primary resistance to adefovir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Virologic response and resistance to adefovir in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Viral features of lamivudine resistant hepatitis B genotypes A and D.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Association between lamivudine sensitivity and the number of substitutions in the reverse transcriptase region of the hepatitis B virus polymerase

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Telbivudine versus lamivudine in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

New paradigms for the treatment of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Chronic hepatitis B--new goals, new treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Combination of alpha-interferon with lamivudine reduces viral breakthrough during long-term therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Adefovir dipivoxil for wait-listed and post–liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Tenofovir therapy for lamivudine resistance following liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Management of drug-resistant chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

Evolution of multi-drug resistant hepatitis B virus during sequential therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970056-8

7 January 2021

10.1016/S1473-3099(09)70056-8

Identifiers

DOI

1 reference

release_oqrwyecyafg2znt7z3opeyogpu

20 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/oqrwyecyafg2znt7z3opeyogpu

24 November 2022

mapped directly with Wikidata item

PubMed ID

19324298

1 reference

PubMed ID

19324298